Institute for Global Health



Evaluating the impact of a national pneumococcal and rotavirus vaccine roll-out on child mortality in Mchinji


Project Summary

The 13-valent pneumococcal conjugate vaccine (PCV-13) and monovalent rotavirus vaccine (RV1) were introduced to the routine infant vaccine schedule in Malawi in November 2011 and October 2012 respectively. Evidence relating to their effectiveness in Sub-Saharan Africa is needed, especially their impact on mortality. 

We are conducting a prospective cohort study in Mchinji district to investigate the impact of these vaccines on all-cause and cause-specific mortality in children aged between 10 weeks and 1 year.

We run a community-based vital events surveillance system, recording all births and deaths of children under the age of 5. We follow all children at 4 months and 1 year to record vaccination and socio-economic status. For all children who die, we conduct a verbal autopsy to ascertain cause of death. 

To date, we have recorded over 40,000 births and 2,000 deaths, in a district of approximately 450,000 residents. Data collection is on-going and results are likely to be reported in the Autumn 2016.

Links to other research

Other research from IGH on Child Health, Cohort Studies, Infectious Diseases and Population Health

Other research from IGH in Malawi